What is Semaglutide?
Semaglutide (aka sema) has emerged as a groundbreaking medication in both type 2 diabetes treatment and obesity management. It is a synthetic peptide drug modeled after a gut hormone called GLP-1, allowing it to mimic natural processes that regulate blood sugar and appetite. Originally developed to improve blood glucose control in diabetes, semaglutide gained widespread attention when studies revealed its remarkable effects on weight loss. In this article, we explain what GLP-1 is, how semaglutide works, its uses in the research and clinical settings, and the key results from major studies over the past decade.
What is GLP-1?
Glucagon-like peptide-1 (GLP-1) is a peptide hormone produced in the gut (specifically by intestinal L-cells) in response to eating. It has several important roles in metabolism and appetite regulation:
- GLP-1 stimulates insulin release from the pancreas when blood sugar is high, helping lower blood glucose levels.
- At the same time, it reduces the release of glucagon from the pancreas, a hormone that normally signals the liver to put more sugar into the bloodstream.
- GLP-1 also slows down stomach emptying, meaning food is digested more slowly and glucose from meals enters the bloodstream gradually.
- In addition, GLP-1 acts on the brain to increase feelings of fullness (satiety) and reduce appetite after eating.
Through these combined actions, our natural GLP-1 hormone helps keep blood sugar in check and tells us to eat less, especially after meals. However, in conditions like type 2 diabetes, the GLP-1 response may be blunted or insufficient. This is where GLP-1–based medications come in.
How Does Semaglutide Work?
Semaglutide is a GLP-1 receptor agonist – in other words, it binds to and activates the same receptors that GLP-1 uses.
Structurally, semaglutide is about 94% identical to human GLP-1, which allows it to mimic the hormone’s effects in the body. By activating GLP-1 receptors in key areas (the pancreas, gastrointestinal tract, and brain), semaglutide enhances the normal responses after a meal.
- In the pancreas, it boosts insulin secretion in a glucose-dependent manner (releasing more insulin only when blood sugar is elevated). It also reduces glucagon release, preventing blood sugar spikes contributing to reduced appetite.
- In the gastrointestinal tract, it slows gastric emptying. This effect, together with the glucagon suppression effect, prevents blood sugar spikes.
- In the brain (particularly the hypothalamus), it helps diminish hunger and increase satiety, so people feel full sooner and eat less.
These multifaceted mechanisms translate into better glucose control and significant weight loss for patients on semaglutide. Because semaglutide is a modified peptide, it has an extended half-life of about one week, allowing for convenient once-weekly dosing in its injectable form.
What is Semaglutide Used for?
Semaglutide is now used in two main arenas of medicine: type 2 diabetes mellitus (T2DM) and weight management for obesity. In the United States, it is available under three different brand names, each with specific indications:
- Ozempic®: a once-weekly injectable form approved for adults with type 2 diabetes to improve blood sugar control. Ozempic is also indicated to reduce the risk of major adverse cardiovascular events (like heart attack or stroke) in patients with T2DM and established heart disease. This cardiovascular benefit is an added bonus observed in trials, especially for patients at high risk.
- Rybelsus®: an oral tablet (taken daily) of semaglutide approved for improving glycemic control in type 2 diabetes. It offers an option for those who prefer pills over injections, though the dose available orally is lower due to absorption limits.
- Wegovy®: a higher-dose semaglutide injection approved for chronic weight management. Wegovy is indicated for adults with obesity (defined by a body mass index ≥30) or those who are overweight (BMI ≥27) with at least one weight-related health condition (such as high blood pressure, type 2 diabetes, or high cholesterol). In these individuals, Wegovy is used alongside diet and exercise to promote sustained weight loss. Notably, semaglutide was the first GLP-1 agonist approved specifically for obesity treatment since liraglutide, and it has shown greater efficacy than previous weight-loss medications.
Side Effects of Semaglutide
The most common side effects of semaglutide are gastrointestinal symptoms – particularly nausea, vomiting, diarrhea, and constipation. These GI side effects are dose-related and tend to be most pronounced when starting the medication or increasing the dose. In the weight loss trials, for example, some participants experienced transient nausea or diarrhea, which generally improved over time. A small percentage of patients discontinue semaglutide due to these side effects (e.g. ~4–5% in trials, mostly due to nausea). To help mitigate this, researchers suggest starting with a low dose and up-titrating slowly so the body can adjust. Other reported side effects include occasional dizziness, mild fast heart rate, fatigue, or injection site reactions, but serious adverse events are relatively rare.
Safety considerations: Semaglutide comes with a boxed warning (similar to other GLP-1 agonists) about a potential risk of thyroid C-cell tumors. This is based on rodent studies in which extremely high doses caused a specific type of thyroid tumor. No cases of this cancer have been seen in human trials, but as a precaution, semaglutide is not given to patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome.
Semaglutide Dosing Protocol (for Research)
Semaglutide is a well-studied medication, and therefore dosing protocols in the research setting have been well-established. The most common research protocol for semaglutide is as follows:
| Phase | Dose & frequency |
|---|---|
| Weeks 1-4 | 0.25 mg once weekly |
| Weeks 5-8 | 0.5 mg once weekly |
| Weeks 9-12 | 1 mg once weekly |
| Week 13 and beyond | 2 mg once weekly |
Note: Titrating to the maximum dose is not required to achieve intended research outcomes.
Shown for education. A licensed clinician should set any actual dose. Compare protocols across peptides in the peptide dosage chart.
Common questions about Semaglutide
What is Semaglutide?
Semaglutide (aka sema) has emerged as a groundbreaking medication in both type 2 diabetes treatment and obesity management. It is a synthetic peptide drug modeled after a gut hormone called GLP-1, allowing it to mimic natural processes that regulate blood sugar and appetite.
What is Semaglutide used for?
Semaglutide is now used in two main arenas of medicine: type 2 diabetes mellitus (T2DM) and weight management for obesity. In the United States, it is available under three different brand names, each with specific indications: Ozempic®; Rybelsus®; Wegovy®.
How does Semaglutide work?
Semaglutide is a GLP-1 receptor agonist – in other words, it binds to and activates the same receptors that GLP-1 uses. Structurally, semaglutide is about 94% identical to human GLP-1, which allows it to mimic the hormone’s effects in the body.
What are the side effects of Semaglutide?
The most common side effects of semaglutide are gastrointestinal symptoms – particularly nausea, vomiting, diarrhea, and constipation. These GI side effects are dose-related and tend to be most pronounced when starting the medication or increasing the dose.
What is the dosage of Semaglutide?
One commonly referenced research protocol is: Weeks 1-4: 0.25 mg once weekly; Weeks 5-8: 0.5 mg once weekly; Weeks 9-12: 1 mg once weekly; Week 13 and beyond: 2 mg once weekly. Shown for education only; a licensed clinician should set any actual dose. See the dosing table.
How do you mix (reconstitute) Semaglutide?
Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.
How much bacteriostatic water do you add to Semaglutide?
There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.
Is Semaglutide FDA-approved?
Semaglutide is FDA-approved in the US for specific indications (status as of October 2026).
References
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44. doi: 10.1056/NEJMoa1607141. View source
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021 Mar 18;384:989-1002. doi: 10.1056/NEJMoa2032183. View source
- Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024 Jul;30:2049-57. doi: 10.1038/s41591-024-02996-7. View source
- Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. View source
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. View source
- Salvador R, et al. Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment. Pharmaceuticals (Basel). 2025 Mar 12;18(3):399. doi: 10.3390/ph18030399. View source
- Tan HC, et al. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37:65-72. doi: 10.15605/jafes.037.02.14. View source
- Wilbon SS, et al. GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes. Cells. 2023;13:65. doi: 10.3390/cells13010065. View source
- Kushner RF, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-61. doi: 10.1002/oby.22794. View source